Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service.
Westerhout KY, Bouwmeester W, Duchesne I, Pisini M, Piena MA, Damele F, Gueron B, Treur M, Belsey J. Westerhout KY, et al. Among authors: treur m. Clinicoecon Outcomes Res. 2017 Feb 27;9:163-172. doi: 10.2147/CEOR.S117650. eCollection 2017. Clinicoecon Outcomes Res. 2017. PMID: 28280374 Free PMC article.
Cost-Utility Analysis of Simeprevir With Peginterferon + Ribavirin (SMV/PR) in the Management of Genotype 1 (G1) and 4 (G4) Hepatitis C Virus (HCV) Infection; from the Perspective of the Uk National Health Service (NHS).
Westerhout KY, Treur M, Mehnert A, Pascoe K, Ladha I, Belsey J. Westerhout KY, et al. Among authors: treur m. Value Health. 2014 Nov;17(7):A679. doi: 10.1016/j.jval.2014.08.2527. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202509 Free article. No abstract available.
Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder.
Verheggen BG, Lee R, Lieuw On MM, Treur MJ, Botteman MF, Kaplan SA, Trocio JN. Verheggen BG, et al. Among authors: treur mj. J Med Econ. 2012;15(3):586-600. doi: 10.3111/13696998.2012.666511. Epub 2012 Feb 24. J Med Econ. 2012. PMID: 22332704 Free article.
23 results